…
MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure, Inc. in January 2008 to reflect its new business plan. MabCure, Inc. was founded in 2006 and is based in White Plains, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 |
| Income before tax | -12.26M | -1.23M | -1.37M | -0.53M | - |
| Net income | -12.45M | -1.43M | -1.39M | -0.53M | -0.11M |
| Selling general administrative | 0.82M | 0.67M | 0.73M | 0.53M | - |
| Selling and marketing expenses | - | - | 0.21M | - | - |
| Gross profit | 0.50M | 0.00M | 0.00M | 0.00M | - |
| Ebit | -0.71M | -1.02M | -1.36M | -0.54M | - |
| Ebitda | -0.68M | -0.98M | -1.31M | -0.53M | -0.11M |
| Depreciation and amortization | 0.03M | 0.04M | 0.05M | 0.01M | - |
| Operating income | -0.71M | -1.02M | -1.36M | -0.54M | -0.11M |
| Other operating expenses | 1.21M | 1.02M | 1.36M | 0.54M | 0.11M |
| Interest expense | 0.19M | 0.21M | 0.02M | 0.00M | - |
| Non recurring | 11.40M | 11.40M | 11.40M | - | - |
| Income tax expense | 0.19M | 0.21M | 0.02M | 0.00M | 0.11M |
| Total revenue | 0.50M | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 1.21M | 1.02M | 1.36M | 0.54M | 0.11M |
| Cost of revenue | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total other income expense net | -11.56M | -0.21M | -0.01M | 0.01M | - |
| Net income from continuing ops | -12.26M | -1.23M | -1.38M | -0.52M | - |
| Net income applicable to common shares | -12.26M | -1.23M | -1.38M | -0.52M | - |
| Breakdown | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 |
| Total assets | 4.81M | 16.21M | 18.94M | 19.49M | - |
| Intangible assets | 4.60M | 16.00M | 18.49M | 18.49M | - |
| Other current assets | 0.01M | 0.01M | 0.03M | 0.02M | - |
| Total liab | 0.94M | 0.48M | 0.83M | 0.29M | 0.05M |
| Total stockholder equity | 3.88M | 15.72M | 18.10M | 19.21M | -0.05M |
| Deferred long term liab | - | 0.02M | - | - | - |
| Other current liab | 0.04M | 0.43M | 0.18M | 0.11M | 0.05M |
| Common stock | 0.06M | 0.06M | 0.06M | 0.06M | 0.03M |
| Retained earnings | -15.51M | -3.24M | -2.01M | -0.64M | -0.11M |
| Other assets | 0.01M | 0.02M | 0.00M | 0.00M | - |
| Cash | 0.15M | 0.00M | 0.21M | 0.81M | - |
| Total current liabilities | 0.94M | 0.47M | 0.78M | 0.19M | 0.05M |
| Net debt | 0.11M | 0.05M | 0.44M | -0.63M | - |
| Short term debt | 0.26M | 0.04M | 0.59M | 0.09M | - |
| Short long term debt | 0.30M | 0.20M | 0.68M | 0.19M | - |
| Short long term debt total | 0.26M | 0.05M | 0.65M | 0.18M | - |
| Other stockholder equity | 19.35M | 18.94M | 20.08M | 19.80M | 0.02M |
| Property plant equipment | 0.04M | 0.12M | 0.17M | 0.17M | - |
| Total current assets | 0.16M | 0.06M | 0.28M | 0.84M | - |
| Net tangible assets | -0.73M | -0.28M | -0.38M | 0.72M | - |
| Net receivables | - | 0.04M | 0.03M | 0.01M | - |
| Long term debt | - | 0.02M | 0.06M | - | - |
| Accounts payable | 0.63M | 0.29M | 0.15M | 0.10M | 0.00M |
| Accumulated other comprehensive income | -0.03M | -0.03M | -0.02M | -0.01M | 0.01M |
| Non currrent assets other | - | 0.02M | 0.00M | 0.00M | - |
| Non current assets total | 4.65M | 16.15M | 18.66M | 18.66M | - |
| Breakdown | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 |
| Change to liabilities | 0.35M | 0.15M | 0.06M | 0.09M | - |
| Total cashflows from investing activities | 0.05M | -0.01M | -0.04M | -0.02M | - |
| Net borrowings | 0.16M | 0.02M | 0.49M | -0.01M | - |
| Total cash from financing activities | 0.17M | 0.50M | 0.49M | 1.44M | 0.05M |
| Change to operating activities | -0.01M | 0.03M | -0.02M | -0.02M | - |
| Net income | -23.63M | -1.23M | -1.37M | -0.53M | -0.11M |
| Change in cash | 0.14M | -0.21M | -0.60M | 0.81M | -0.04M |
| Begin period cash flow | 0.00M | 0.21M | 0.81M | - | 0.04M |
| End period cash flow | 0.15M | 0.00M | 0.21M | 0.81M | - |
| Total cash from operating activities | -0.06M | -0.69M | -1.03M | -0.46M | -0.09M |
| Depreciation | 0.03M | 0.04M | 0.04M | 0.00M | - |
| Other cashflows from investing activities | 0.05M | -0.00M | -0.00M | - | - |
| Change to account receivables | 0.04M | -0.02M | -0.02M | -0.01M | - |
| Sale purchase of stock | 0.02M | 0.50M | 0.50M | 1.30M | - |
| Other cashflows from financing activities | 0.28M | 0.04M | 0.54M | 0.25M | - |
| Change to netincome | 11.78M | 0.33M | 0.29M | 0.00M | - |
| Capital expenditures | 0.00M | 0.01M | 0.04M | 0.17M | 0.00M |
| Change in working capital | 0.39M | 0.16M | 0.02M | 0.06M | 0.01M |
| Stock based compensation | 0.21M | 0.13M | 0.24M | - | - |
| Other non cash items | -0.69M | 0.20M | 0.05M | 0.01M | 0.01M |
| Free cash flow | -0.06M | -0.71M | -1.08M | -0.63M | -0.09M |
Sector: Technology Industry: Solar
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MBCI MabCure Inc |
- -% |
0.00 | - | - | 0.00 | 0.06 | 1.29 | -0.05 |
| FSLR First Solar Inc |
- -% |
151.95 | 13.14 | 11.49 | 3.84 | 2.17 | 3.54 | 8.58 |
| NXT Nextpower Inc. |
- -% |
75.95 | 21.39 | 18.42 | 3.38 | 4.90 | 3.30 | 15.84 |
| ENPH Enphase Energy Inc |
- -% |
21.98 | 136.61 | 18.32 | 6.79 | 9.24 | 6.51 | 53.17 |
| XISHY Xinyi Solar Holdings Limited |
-0.70 13.21% |
4.60 | 11.55 | 14.93 | 0.22 | 1.24 | 0.24 | 1.12 |
MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure, Inc. in January 2008 to reflect its new business plan. MabCure, Inc. was founded in 2006 and is based in White Plains, New York.
21 Sparrow Circle, White Plains, NY, United States, 10605
845 591 3144
3
| Name | Title | Year Born |
|---|---|---|
| Mr. Jehu Thomas Degerold Hand | Chief Exec. & Financial Officer and Director | 1957 |
| Kimberly Peterson | Corp. Sec. | NA |
| Mr. Jehu Thomas Degerold Hand Esq. | Chief Executive & Financial Officer and Director | 1957 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.